Price: $772.77, Change: $+10.67, Percent Change: +1.40%
Related Articles
Wire
Summit Therapeutics Shares Fall After HC Wainwright Downgrade
Summit Therapeutics (SMMT) shares fell nearly 2% in intraday trading on Friday after HC Wainwright downgraded the stock to neutral from buy.Trading volume stood at about 4.2 million shares, compared with a daily average of over 3.4 million.Price: $17.15, Change: $-0.32, Percent Change: -1.83%
$SMMT
Wire
Gilead Sciences Gets FDA Approval for Hepcludex
Gilead Sciences (GILD) has received approval from the US Food and Drug Administration for Hepcludex to treat chronic hepatitis delta virus infection in adults without advanced liver scarring, or with compensated cirrhosis, the FDA said Friday.The therapy is the first FDA-approved treatment for chronic HDV infection, a serious condition that can cause liver fibrosis, liver cancer, liver failure, and even death, the regulator said.The efficacy of Hepcludex was shown in a phase 3 trial, it said.Shares were up over 2% in afternoon trading.Price: $133.74, Change: $+3.24, Percent Change: +2.48%
$GILD
Wire
Scilex Approves Dividend of Semnur Shares to Stockholders
Scilex Holding (SCLX) said Friday its board approved a dividend of Semnur Pharmaceuticals' common stock held by the company to its stockholders and certain eligible equity holders.The record date for the dividend is June 1, and the board will set the payment date within 60 days of that date.Holders as of the record date will receive one Semnur common share for each Scilex common share held, or for each share issuable upon exercise or conversion of eligible securities.Scilex said it holds 186 million Semnur shares and plans to distribute about 10.7 million under the approved ratio.The board may change the record date or revoke the dividend before payment if solvency or surplus conditions change, the company said.Scilex's Semnur stake dates back to a 2019 corporate transaction.Price: $6.07, Change: $+0.15, Percent Change: +2.45%
$SCLX